{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:02:39Z","timestamp":1787896959095,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jpba.2023.115932","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T11:15:42Z","timestamp":1703934942000},"page":"115932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring"],"prefix":"10.1016","volume":"240","author":[{"suffix":"III","given":"Raymond E.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Oberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"Riddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Devanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115932_bib1","unstructured":"World Health Organization (WHO), HIV and AIDS Key Facts, (2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids (accessed April 18, 2023)."},{"key":"10.1016\/j.jpba.2023.115932_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","article-title":"Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis","volume":"18","author":"Teeraananchai","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.jpba.2023.115932_bib3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"HPTN 052 study team, antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2023.115932_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25408","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"Tolley","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jpba.2023.115932_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","article-title":"Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research","volume":"17","author":"Cobb","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jpba.2023.115932_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11904-020-00502-5","article-title":"Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions","volume":"17","author":"Spinelli","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jpba.2023.115932_bib7","unstructured":"U.S. Department of Human and Health Services (DHHS)Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"key":"10.1016\/j.jpba.2023.115932_bib8","unstructured":"Food and Drug Administration, Bioanalytical Method Validation: Guidance for Industry, (2018). https:\/\/www.fda.gov\/media\/70858\/download (accessed April 14, 2023)."},{"key":"10.1016\/j.jpba.2023.115932_bib9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jchromb.2009.04.046","article-title":"Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS\/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells","volume":"877","author":"Elens","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115932_bib10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FTD.0b013e3181c05adf","article-title":"Validation of an electrospray ionization LC-MS\/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples","volume":"31","author":"Quaranta","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115932_bib11","unstructured":"Triumeq [package insert]. ViiV Healthcare. Research Triangle Park, NC, (2014)."},{"key":"10.1016\/j.jpba.2023.115932_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2023.115932_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","article-title":"Bictegravir: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115932_bib14","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1111\/bcp.15439","article-title":"Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects","volume":"88","author":"Han","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115932_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13318-018-0497-3","article-title":"Clinical pharmacokinetics and drug interactions of doravirine","volume":"43","author":"Wilby","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2023.115932_bib16","unstructured":"Truvada [package insert]. Gilead Sciences, Inc. Foster City, CA, (n.d.). https:\/\/www.gilead.com\/\u223c\/media\/Files\/pdfs\/medicines\/hiv\/truvada\/truvada_pi.pdf (accessed October 5, 2020)."},{"key":"10.1016\/j.jpba.2023.115932_bib17","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/jac\/dkz217","article-title":"Swiss HIV Cohort Study, population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting","volume":"74","author":"Barcelo","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2023.115932_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/cpt.1464","article-title":"Population modeling highlights drug disposition differences between tenofovir alafenamide and tenofovir disoproxil fumarate in the blood and semen","volume":"106","author":"Greene","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2023.115932_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.jpba.2023.115932_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30902-7","article-title":"Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation","volume":"13","author":"Deodhar","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852300701X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852300701X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:37:23Z","timestamp":1760002643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852300701X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"alternative-id":["S073170852300701X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115932","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115932"}}